Health Care

Roche’s KRAS G12C inhibitor tops rivals in NSCLC, driving Swiss shares 4 % higher with 45 % response rate and 18.4 mo OS—boosting precision‑oncology prospects and investor confidence.

Explore The Cigna Group’s 2025‑26 Annual Report: how the firm is boosting recurring revenue, expanding in India’s Tier‑II/III markets and the GCC, and leveraging a digital, distribution‑led wealth‑management model for sustainable growth.

Insulet Corp’s directors boost ownership through deferred‑stock conversions, reinforcing alignment with shareholders while staying fully compliant with SEC Form 4 filings.

AbbVie’s July 2026 moves—insider equity purchases, the Apogee Therapeutics acquisition and a new Phase 2 oncology trial—show a strategic pivot to diversify its biologics pipeline, beat the Humira patent cliff and boost shareholder confidence.

Ruveon, Bayer’s new U.S. subsidiary, streamlines glyphosate operations and legal defense after a Supreme Court ruling, boosting compliance, efficiency, and investor confidence.

Merck KGaA lifts its voting‑rights stake to 8%, meeting German disclosure rules—no control shift, just transparent ownership for investors.

UnitedHealth Group tops Q2 2026 expectations with $27.8 bn revenue, $8.12 EPS and strong cash flow, underscoring resilient margins and a disciplined capital‑allocation strategy.

Explore how Novo Nordisk’s supplier‑discount strategy reshapes pharma pricing, value‑based reimbursement, and supply‑chain resilience, while safeguarding patient outcomes.

Johnson & Johnson’s Q2 earnings spark market gains, showcasing double‑digit sales growth, margin expansion, and a resilient healthcare strategy that outpaces peers and boosts investor confidence.

European markets finish the week on a muted yet positive note as health‑sector gains, especially Fresenius Medical Care’s voting‑rights disclosure, offset geopolitical uncertainties, highlighting the sector’s defensive resilience and investor confid…